Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Histopathology. 2020 Oct 12;78(4):498–507. doi: 10.1111/his.14241

Figure 2.

Figure 2.

Somatic mutations and copy number alterations identified by Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) next-generation sequencing assay in 14 ASCO/CAP ISH Group 4, 24 Group 5 and 8 Group 1 breast carcinoma cases. Cases are represented in columns, and genes are displayed in rows. Alteration types are color-coded according the legend. Copy number alterations in ERBB2 and RARA were significant associated with Group 1 cases on univariate analysis with Fisher exact test (P < .001) and when adjusted for multiple comparisons (P = .01). Values written in red denote significant P < .05.